DOT (directly observed therapy) in diabetes: Current thought, future reality

Australian Journal of Rural Health

Volumn 22, Issue 4, 2014, Pages 206-206

  Kalra, Sanjay ^a   Gupta, Yashdeep ^b  

^a BHARTI HOSPITAL   (India)

^b Government Medical College and Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DIRECTLY OBSERVED THERAPY; HUMAN; MEDICATION COMPLIANCE; PROCEDURES; PSYCHOLOGY;

DIABETES MELLITUS; DIRECTLY OBSERVED THERAPY; HUMANS; MEDICATION ADHERENCE;

EID: 84906049657     PISSN: 10385282     EISSN: 14401584     Source Type: Journal    
DOI: 10.1111/ajr.12123     Document Type: Article

References (5)

1. Vitoria M, Granich R, Gilks CF etal. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. American Journal of Clinical Pathology 2009; 131: 844-848.
2. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology 2012; 10: 407-416.
3. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet Infectious Diseases 2009; 9: 737-746.
4. Keating GM. Insulin degludec and insulin degludec/insulin as part: a review of their use in the management of diabetes mellitus. Drugs 2013; 73: 575-593.
5. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 2012; 8: 728-742.